Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

AltaPointe Health Warns About New Drug Trend Combining Fentanyl with Animal Tranquilizer, Commonly Known as Tranq
  • USA - English


News provided by

AltaPointe Health

Mar 16, 2023, 21:00 ET

Share this article

Share toX

Share this article

Share toX

AltaPointe Health is an extensive mental health and family medical healthcare system in Alabama, providing more than 1.3 million hospital, outpatient, residential and crisis services annually.
AltaPointe Health is an extensive mental health and family medical healthcare system in Alabama, providing more than 1.3 million hospital, outpatient, residential and crisis services annually.

As the powerful synthetic opioid fentanyl continues to spread, a new additive is raising even more concern. AltaPointe Health Deputy Chief Medical Officer and Addiction Medicine Fellowship Program Director for the University of South Alabama College of Medicine Luke J. Engeriser, MD, says people are combining fentanyl and an animal tranquilizer, xylazine, also known as tranq, to extend fentanyl's effects. Xylazine, commonly used by veterinarians as a sedative for large animals like horses and cows, is not approved for human use. It can increase the risk of a fatal overdose when combined with fentanyl because it can exacerbate the respiratory depression that opioids cause. It can also cause large wounds that may result in amputation, as well as intense withdrawal symptoms.

MOBILE, Ala., March 16, 2023 /PRNewswire-PRWeb/ -- As the powerful synthetic opioid fentanyl continues to spread, a new additive is raising even more concern. AltaPointe Health Deputy Chief Medical Officer and Addiction Medicine Fellowship Program Director for the University of South Alabama College of Medicine Luke J. Engeriser, MD, says people are combining fentanyl and an animal tranquilizer, xylazine, also known as tranq, to extend fentanyl's effects.

Xylazine, commonly used by veterinarians as a sedative for large animals like horses and cows, is not approved for human use. It can increase the risk of a fatal overdose when combined with fentanyl because it can exacerbate the respiratory depression that opioids cause.

"Lately, tranq has been a much bigger part of the overdose deaths. I am increasingly concerned," said Dr. Engeriser. "It has devastated the Philadelphia community, and I'm hoping it does not become a big problem in our area."

Narcan (naloxone), widely distributed to treat opioid overdoses, will not help patients using tranq because it is not an opioid. Narcan would counteract the fentanyl, but the animal tranquilizer would require additional medical care.

SIDE EFFECTS

In addition to extreme sleepiness, blackouts, and depressed breathing/heart function, tranq users experience large wounds that do not heal, resulting in skin rot and even amputation.

Withdrawals from xylazine can cause intense anxiety and dysphoria. And like overdose concerns, the withdrawals cannot be managed with typical opioid treatments such as buprenorphine and methadone.

The White House is investigating tranq as a potential "emerging threat," which could lead to the development a federal plan for addressing the drug.

UNINTENTIONAL USE

While some users may intentionally use tranq to extend the effects of fentanyl, in many cases, people are unaware that it has been cut into other drugs. This is another alarming example of how dangerous illegal street drugs have become.

AltaPointe administers drug screenings to potential clients to identify how best to serve them. Misty Bowen, director of AltaPointe's substance abuse services, says most people are shocked by the results.

"They may say 'well, I did some cocaine yesterday, or some methamphetamine.' And they may say 'well, I've been taking oxycodone pills.' But when we administer the test and read the results, we see the cocaine, or the methamphetamine, or the oxycodone, but fentanyl is in there as well," explained Bowen. "They are shocked because they had no idea that they even used fentanyl, but it is showing up everywhere. And our fear is tranq will do the same."

SUBSTANCE USE TREATMENT

So far, tranq has not been tied to overdose deaths along the Gulf Coast. Healthcare professionals urge users, or anyone struggling with addiction, to seek treatment and begin the road to recovery.

"We have an extensive continuum of care to help you with your substance use disorder. We want you to know recovery is possible and AltaPointe offers free treatment for qualifying individuals. I encourage you to take the first step and call for help," Bowen added.

For more information on AltaPointe Health's substance use programs, visit AltaPointe.org or call (251) 450-2211.

ABOUT ALTAPOINTE
AltaPointe Health is an extensive mental health and family medical healthcare system. Our clinicians provide more than 1.3 million hospital, outpatient, residential and crisis services annually. AltaPointe's access to care line answers 76,175 calls for help each year from the community.

Media Contact

April Douglas, Director of Public Relations, AltaPointe Health, (251) 544-4639, [email protected]

Twitter

SOURCE AltaPointe Health

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.